Similar articles

• [GPs: patients require you to doubt! Interview by Catherine Holué].

  Viollet V. Viollet V. Rev Prat. 2012 Jan;62(1):85-6. Rev Prat. 2012. PMID: 22335075 French. No abstract available.
• [Rare diseases: "a public health priorty". Interview by Catherine Holué].

  Podeur A. Podeur A. Rev Prat. 2012 Jan;62(1):79-80. Rev Prat. 2012. PMID: 22335073 French. No abstract available.
• [Neuromuscular diseases are many but rare].

  Lindvall B. Lindvall B. Lakartidningen. 2013 Apr 10-16;110(15):752-3. Lakartidningen. 2013. PMID: 23662534 Review. Swedish. No abstract available.
• [Health technology assessment in the field of rare diseases at Haute Autorité de Santé in France].

  Bélorgey C. Bélorgey C. Med Sci (Paris). 2018 May;34 Hors série n°1:49-50. doi: 10.1051/medsci/201834s126. Epub 2018 Jun 18. Med Sci (Paris). 2018. PMID: 29911564 French. No abstract available.
• Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy.

  Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A, Pereda A, Hemmings R, Campion G, Kaye E, Arechavala-Gomeza V, Goyenvalle A, Niks E, Veldhuizen O, Furlong P, Stoyanova-Beninska V, Wood MJ, Johnson A, Mercuri E, Muntoni F, Sepodes B, Haas M, Vroom E, Aartsma-Rus A. Straub V, et al. Lancet Neurol. 2016 Jul;15(8):882-890. doi: 10.1016/S1474-4422(16)30035-7. Lancet Neurol. 2016. PMID: 27302365 Review.